as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹82.22
Change
+0.02 (0.02%)
Open
₹82.52
Prev. Close
₹82.2
Day High
₹83.0
Day Low
₹82.17
Volume Analysis
Traded
2,241,222
Delivered
1,430,954
Delivery %
63.85%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (28.9%)
- •Strong operating margin (58.0%)
Weaknesses (0)
No signal for this stock
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹83.58 | ₹83.29 | ₹82.75 | ₹82.46 | ₹81.92 | ₹81.63 | ₹81.09 |
| Fibonacci | ₹83.29 | ₹82.97 | ₹82.78 | ₹82.46 | ₹82.14 | ₹81.95 | ₹81.63 |
| Camarilla | ₹82.45 | ₹82.37 | ₹82.3 | ₹82.46 | ₹82.14 | ₹82.07 | ₹81.99 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
+0.02%
1 Month
+20.28%
3 Months
+86.61%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹5.5
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
19.02%
Net margin 38.94% × asset turnover 0.33x × equity multiplier 1.48x
Company Overview
Sector
Healthcare
Market Cap
₹3,639 Cr
P/E (TTM)
82.1
ROE
28.9%
Book Value
₹2.69
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Shukra Pharmaceuticals L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (28.9%); strong operating margin (58.0%).
TopFund Score — Fundamentals Quality
65/100 — GoodData confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- −Stock is trading at 30.6 times its book value
- −Debtor days have increased from 123 to 148 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Q2 FY27 revenue rose 652% to Rs44.20 crore; net profit increased to Rs16.01 crore.
No deviation in utilization of Rs 10.46 crore preferential warrant proceeds for Q2 FY27.
Board approved Q2/H1 FY27 results; name changed to Shukra Medtech, warrants converted.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 11 | 13 | 5 | 6 | 39 | 6 | 24 | 44 |
| Expenses + | 7 | 6 | 4 | 6 | 12 | 6 | 4 | 26 |
| Operating Profit | 4 | 7 | 1 | 0 | 27 | 1 | 19 | 19 |
| OPM % | 37.0% | 55.0% | 24.0% | -7.0% | 69.0% | 11.0% | 81.0% | 42.0% |
| Other Income + | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 8 | 1 | 0 | 27 | 0 | 18 | 18 |
| Tax % | 23.0% | 29.0% | 26.0% | -1,090.0% | 24.0% | 553.0% | 29.0% | 29.0% |
| Net Profit + | 3 | 5 | 1 | 2 | 20 | -2 | 13 | 13 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 270 | -52 | 336 | 652 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| Sales + | 33 | 57 | 113 |
| Expenses + | 20 | 28 | 48 |
| Operating Profit | 13 | 29 | 66 |
| OPM % | 39.0% | 51.0% | 58.0% |
| Other Income + | 4 | 5 | 3 |
| Interest | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 4 |
| Profit before tax | 13 | 29 | 63 |
| Tax % | 28.0% | 23.0% | — |
| Net Profit + | 10 | 22 | 44 |
| EPS in Rs | 0 | 1 | 1 |
| Dividend Payout % | 5.0% | 2.0% | — |
| Sales growth | — | 74 | 222 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|
| Reserves | 19 | 46 | 74 |
| Borrowings + | 4 | 5 | 22 |
| Other Liabilities + | 20 | 23 | 34 |
| Total Liabilities | 87 | 117 | 175 |
| Fixed Assets + | 19 | 22 | 21 |
| CWIP | 2 | 12 | 26 |
| Investments | 0 | 0 | 0 |
| Other Assets + | 65 | 84 | 128 |
| Total Assets | 87 | 117 | 175 |
| Equity Capital | 44 | 44 | 44 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity + | 8 | 3 |
| Cash from Investing Activity + | -1 | -14 |
| Cash from Financing Activity + | -5 | 5 |
| Net Cash Flow | 2 | -6 |
| Free Cash Flow | 5 | -13 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 92 | 17 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.92% | 48.93% | 48.2% |
| Promoters | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 51.16% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.43% |
| DII | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.21% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Shukra Pharmaceuticals L (this stock) | 3,639 | 82.1 | 30.56 | 28.9% |
| Unichem Laboratories Ltd | 3,511 | 29.5 | 1.26 | 3.17% |
| Solara Active Pha Sci Ltd | 3,347 | 70.7 | 2.33 | -0.13% |
| Advanced Enzyme Tech Ltd | 3,102 | 19.1 | 1.9 | 10.5% |
| Rpg Life Sciences Ltd | 4,310 | 37.6 | 6.26 | 19.3% |
| Kwality Pharmaceuticals L | 4,370 | 45.3 | 11.31 | 22.6% |
| Ind Swift Laboratories Lt | 2,881 | 31.4 | 1.95 | 4.02% |
Which Mutual Funds Hold Shukra Pharmaceuticals L?
Frequently Asked Questions about Shukra Pharmaceuticals L
Shukra Pharmaceuticals L (SHUKRAPHAR) closed at ₹82.22 on NSE on 19 November 2026, up 0.02 (0.02%) from the previous close.
Shukra Pharmaceuticals L trades on the NSE (National Stock Exchange of India) under the symbol SHUKRAPHAR.
Shukra Pharmaceuticals L has a trailing twelve-month P/E (price-to-earnings) ratio of 82.1.
Shukra Pharmaceuticals L has a dividend yield of 0.01%.
Shukra Pharmaceuticals L's 52-week high is ₹84.8 and its 52-week low is ₹26.3.
Shukra Pharmaceuticals L has a market capitalisation of ₹3,639 crore.
Shukra Pharmaceuticals L has a TopFund Quality Score of 65/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Shukra Pharmaceuticals L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.